Fixed drug combinations in the treatment of hypertension: How to identify the optimal dose

Journal of Hypertension, Supplement

Volumn 16, Issue 1, 1998, Pages

  Messerli, Franz H ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Combination therapy; Factorial design; Food and drug administration requirements; Hypertension; Optimal dose

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ARTERIAL PRESSURE; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; HEART; HYPERTENSION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; TARGET ORGAN;

EID: 0031932354     PISSN: 09521178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Chalmers J. The place of combination therapy in the treatment of hypertension in 1993. Clin Exp Hypertens 1993; 15:1299-1313.
2. Messerli FH, Ketelhut R. Left ventricular hypertrophy: a pressure-independent cardiovascular risk factor. J Cardiovasc Pharmacol 1993; 22 (suppl 1 ):S7-S13.
3. Aronson J. Beneficial drug interactions. Practitioner 1994; 238:514-518.
4. Reid JL. Pharmacokinetic and pharmacodynamic aspects of the choice of components of combination therapy. J Hum Hypertens 1995; 9 (suppl 4):S19-S23.
5. Jakobsen J, Glaus L, Graf P, et al. Unmasking of the hypotensive effect of nifedipine in normotensives by addition of the angiotensin converting enzyme inhibitor benazepril. J Hypertens 1992; 10:1045-1051.